RAF1 antibody
Principal name
RAF1 antibody
Alternative names for RAF1 antibody
C-RAF, Raf-1, cRaf, RAF proto-oncogene serine/threonine-protein kinase
SwissProt ID
A7E3S4 (Bovin), P04049 (Human), P05625 (Chick), P09560 (Xenla), P11345 (Rat), Q99N57 (Mouse)
Ncbi ID
NP_002871.1, NP_002871, 9606, 10116, NP_036771.1, NM_002880.2, NM_029780, NM_012639, NM_002880, NP_084056.1
Available reactivities
Available hosts
Available applications
Immunoprecipitation (IP), Western blot / Immunoblot (WB), Paraffin Sections (P), Enzyme Immunoassay (E), Immunocytochemistry/Immunofluorescence (ICC/IF), Dot blot (Dot), ELISA (detection) (E(detection)), Flow Cytometry (F)
Background of RAF1 antibody
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation.
Immunoblot Analysis A431 cell lysate probed with mab C-Raf (PBB-1) at 0.1 µg/ml.
Figure 1. Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Raf-1 (phospho-Ser259) antibody AP02308PU
Figure 2. Western blot analysis using Raf-1 antibody AP02550PU (Line 1, 2, and 3) and Raf-1 (phospho-Ser259) antibody AP02308PU (Line 4, 5, and 6).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Raf-1 antibody (AP02550PU-S; AP02550PU-N).
Western blot analysis of extracts using Raf-1 antibody (Line 1, 2, and 3) and Raf-1 (pSer259) antibody (AP02550PU-S; AP02550PU-N, Line 4, 5, and 6).
Immunohistochemistry (IHC) analyzes of Raf1 antibody (Cat.-No.: AP06299PU-N) in paraffin-embedded human breast carcinoma tissue.
Western blot (WB) analysis of Raf1 antibody (Cat.-No.: AP06299PU-N) in extracts from K562 MDA-MB-435 cells.
Immunohistochemistry (IHC) analyzes of Raf1 antibody (Cat.-No.: AP06438PU-N) in paraffin-embedded human lung carcinoma tissue.
Western blot (WB) analysis of Raf1 antibody (Cat.-No.: AP06438PU-N) in extracts from HeLa cells treated with UV 5'.
Kidney: Formalin-Fixed Paraffin-Embedded (FFPE)
Figure 1. Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Raf1 Antibody AP08058PU.
Figure 2. Western blot analysis of extract from 293 cell, using Raf1 Antibody AP08058PU (Lane 1 and 2).
Dot blot analysis of RAF1 (phospho S338) polyclonal antibody ( Cat # PAB0590 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5 µg/ml.
Dot blot analysis of RAF1 (phospho S296) polyclonal antibody ( Cat # PAB0591 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibodies working concentration was 0.5 µg/ml.
RAF1 (phospho S43) polyclonal antibody ( Cat # PAB0592 ). Western blot analysis of RAF1 expression in human kidney.
Dot blot analysis of RAF1 (phospho S43) polyclonal antibody ( Cat # PAB0592 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antobodies working concentration was 0.5 µg/ml.
Dot blot analysis of RAF1 (phospho S471) polyclonal antibody ( Cat # PAB0593 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentration was 0.5 µg/ml. P-Pab : phospho-antibody; P-Peptide : phospho-peptide; NP-Peptide : non-phospho-peptide.
Dot blot analysis of RAF1 (phospho T269) polyclonal antibody ( Cat # PAB0594 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentration was 0.5 µg/ml. P-Pab : phospho-antibody; P-Peptide : phospho-peptide; NP-Peptide : non-phospho-peptide.
Dot blot analysis of RAF1 (phospho S339) polyclonal antibody ( Cat # PAB1669 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5 µg/ml.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with RAF1 polyclonal antibody ( Cat # PAB3487 ) , which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry ; clinical relevance has not been evaluated. BC = breast carcinoma.
Western blot analysis of RAF1 polyclonal antibody ( Cat # PAB3487 ) in Jurkat cell lysate. RAF1 ( arrow ) was detected using purified polyclonal antibody. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.
Proximity Ligation Analysis (PLA) of protein-protein interactions between PDGFRB and RAF1. Huh7 cells were stained with anti-PDGFRB rabbit purified polyclonal 1:600 and anti-RAF1 mouse monoclonal antibody 1:100. Signals were detected by Duolink® 30 Detection Kit 613(red), and nuclei were counterstained with DAPI (blue). Each red dot represents the detection of protein-protein interaction complex.
Proximity Ligation Analysis (PLA) of protein-protein interactions between BAD and RAF1. HeLa cells were stained with anti-BAD rabbit purified polyclonal 1:1200 and anti-RAF1 mouse monoclonal antibody 1:50. Signals were detected by Duolink® 30 Detection Kit 613(red), and nuclei were counterstained with DAPI (blue). Each red dot represents the detection of protein-protein interaction complex.
Western blot analysis of RAF1 over-expressed 293 cell line, cotransfected with RAF1 Validated Chimera RNAi ( Cat # H00005894-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with RAF1 monoclonal antibody (M03) clone 1H4 (Cat # H00005894-M03 ). GAPDH ( 36.1 kDa ) used as specificity and loading control.
Western Blot analysis of RAF1 expression in transfected 293T cell line by RAF1 monoclonal antibody (M03), clone 1H4.Lane 1: RAF1 transfected lysate(73.1 KDa).Lane 2: Non-transfected lysate.
Immunofluorescence of purified MaxPab antibody to RAF1 on HeLa cell. [antibody concentration 10 ug/ml]
Western Blot analysis of RAF1 expression in transfected 293T cell line (H00005894-T01) by RAF1 MaxPab polyclonal antibody.Lane 1: RAF1 transfected lysate(71.28 KDa).Lane 2: Non-transfected lysate.
Immunohistochemistry (IHC) analyzes of Raf1 pSer259 antibody (Cat.-No.: AP01674PU-N) in paraffin-embedded human breast carcinoma tissue.
Western blot (WB) analysis of Raf1 pSer259 antibody (Cat.-No.: AP01674PU-N) in extracts from K562 or MDA-MB-435 cells.
Dot blot analysis of Phospho-RAF1-S296 Pab (Cat.#AP12748PU-N) on nitrocellulose membrane. Dot blot analysis of Phospho-RAC1-Ser71 Pab (Cat.#AP12748PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibodies working concentration was 0.5ug per ml.
Dot blot analysis of Phospho-RAF1-S43 Phospho-specific Pab (Cat#AP12784PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antobodies working concentration was 0.5ug per ml.
Dot blot analysis of Phospho-RAF1-Ser471 polyclonal antibody (Cat#AP12786PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentration was 0.5ug per ml. P-Pab: phospho-antibody; P-Peptide: phospho-peptide; NP-Peptide: non-phospho-peptide.
Dot blot analysis of Phospho-RAF1-Thr269 polyclonal antibody (Cat#AP12797PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentration was 0.5ug per ml. P-Pab: phospho-antibody; P-Peptide: phospho-peptide; NP-Peptide: non-phospho-peptide.
Figure 1. (LEFT) Dot blot analysis of anti-RAF1-pSer338 Phospho-specific Pab (Cat#AP12801PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml. (RIGHT) Western blot analysis of Phospho-RAF1-pSer338 Antibody in human TPA activated Hela cell line lysates. Phospho-RAF1 (arrow) was detected using the purified PAb. (0: without TPA; 1: 60ug/ml TPA, 15min; 2: 60ug/ml TPA, 30min; 3: 60ug/ml TPA, 45min; 4: 125ug/ml TPA, 15min; 5: 125ug/ml TPA, 30min; 6: 125ug/ml TPA, 45min; 7: 250ug/ml TPA, 15min; 8: 250ug/ml TPA, 30min; 9: 250ug/ml, 45min)
Dot blot analysis of anti-RAF1-pSer259 Phospho-specific Pab (Cat#AP12862PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Dot blot analysis of anti-RAF1-pTyr340 Phospho-specific Pab (Cat#AP12864PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Dot blot analysis of anti-RAF1-pSer494 Phospho-specific Pab (Cat#AP12876PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Dot blot analysis of anti-RAF1-pTyr341 Phospho-specific Pab (Cat#AP12891PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Dot blot analysis of Phospho-specific Pab anti-RAF1 pSer339 (Cat.#AP12926PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining.
Western blot analysis of anti-RAF1 Pab in Jurkat cell lysate. RAF1 (arrow) was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.
Immunoblot analysis of cell lysates.Lane 1 : HeLa cell lysate. Lnae 2 : 293T cell lysate.Lane 3 : NIH/3H3 cell lysate.Lane 4 : C6 cell lysate.
Western blot of GST fusion protein containing human RAF1. The blot was probed with RAF1 polyclonal antibody ( Cat # PAB7870 ) in the presence (lane 2) or absence (lane 1) of RAF1 (C-terminus) blocking peptide (lane 2).
Dot blot analysis of RAF1 (phospho S259) polyclonal antibody ( Cat # PAB8117 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5 µg/ml.
Dot blot analysis of RAF1 (phospho Y340) polyclonal antibody ( Cat # PAB8119 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5 µg/ml.
Dot blot analysis of RAF1 (phospho S494) polyclonal antibody ( Cat # PAB8133 ) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5 µg/ml.
Western blot of UV treated human Jurkat cell lysate showing specific immunolabeling of the ~74k Raf1 protein (Control). The phosphospecificity of this labeling is shown in the second lane (lambda-phosphatase: l-Ptase). The blot is identical to the control except that it was incubated in l-Ptase (1200 units for 30 min) before being exposed to the Raf1 (phospho S301) polyclonal antibody ( Cat # PAB9647 ). The immunolabeling of Raf1 is completely eliminated by treatment with l-Ptase.
Figure 1. Western blot of UV treated human Jurkat cell lysate showing specific immunolabeling of the ~74k Raf-1 protein (Control). The phosphospecificity of this labeling is shown in the second lane (lambda-Phosphatase). The blot is identical to the control except that it was incubated in lambda-Ptase (1200 units for 30 min) before being exposed to the phospho Ser301 Raf-1 antibody. The immunolabeling of Raf-1 is completely eliminated by treatment with lambda-Ptase.
Formalin-fixed, paraffin-embedded human tonsil stained with RAF1 monoclonal antibody, clone PS338 [DPR/2/2A/3A] ( Cat # MAB5144 ) using peroxidase-conjugate and AEC chromogen. Note nuclear staining of mucous epithelium.
Figure 1. Western blot analysis of extracts from MDA-MB-435 cells treated with PMA using Raf1 (phospho-Ser338) antibody AP09462PU.
Immunohistochemistry analyzes of C-Raf antibody (AP20214PU-N) in paraffin-embedded human brain tissue.
Western blot analysis of C-Raf antibody (AP20214PU-N) in extracts from 293 cells.
Immunohistochemistry analyzes of C-Raf antibody (AP20215PU-N) in paraffin-embedded human breast carcinoma tissue.
Western blot analysis of C-Raf antibody (AP20215PU-N) in extracts from 293 cells.
Western blot analysis of RAF1 Antibody (Cat.-No AP20499PU-N) in extracts from HT-29 cells.
Western blot analyzes of Raf-1 antibody (Cat.-No.: AP20700PU-N) in extracts from RAW264.7 cells.
Immunohistochemistry (IHC) analyzes of p-c-RAF (pSer259) pAb in paraffin-embedded human prostate carcinoma tissue.
Western blot (WB) analysis of p-c-RAF (pSer259) pAb in extracts from K562 cells.
Immunohistochemistry (IHC) analyzes of c-RAF antibody (Cat.-No.: AP20995PU-N) in paraffin-embedded human breast carcinoma tissue.
Western blot (WB) analyzes of c-RAF antibody (Cat.-No.: AP20995PU-N) in extracts from K562 cells.
Immunohistochemistry (IHC) analyzes of Raf-1 antibody (Cat.-No.: AP21123PU-N) in paraffin-embedded human brain tissue.
Western blot (WB) analysis of Raf-1 antibody (Cat.-No.: AP21123PU-N) in extracts from hela cells.
Immunohistochemical analysis of paraffin-embedded liver cancer tissues using RAF1 antibody Cat.-No AM06729PU-N with DAB staining.
Western blot analysis using RAF1 antibody Cat.-No AM06729PU-N against Hela (1), A431 (2), Cos7 (3) and C6 (4) cell lysate.
Western blot analysis using RAF1 antibody Cat.-No AM06729PU-N against human RAF1 (AA: 198-407) recombinant protein (Expected MW is 73 kDa).
Flow cytometric analysis of Hela cells using RAF1 antibody Cat.-No AM06729PU-N (green) and negative control (red).
Immunohistochemical analysis of paraffin-embedded human pancreas tissue using Raf1 (Phospho-Tyr341) antibody AP55703PU-N (left)or the same antibody preincubated with blocking peptide (right).
Western blot analysis of extracts from Jurkat cells treated with Paclitaxel using Raf1 (Phospho-Tyr341) Antibody AP55703PU-N.The lane on the right is treated with the antigen-specific peptide.
Immunohistochemical analysis of paraffin-embedded human brain tissue using C-RAF (Phospho-Thr269) antibody AP55772PU-N (left)or the same antibody preincubated with blocking peptide (right).
Western blot analysis of extracts from 293 cells treated with PMA using Phospho-C-RAF (Ser296) antibody AP55888PU-N.The lane on the right is treated with the antigen-specific peptide.
Immunofluorescent analysis of c-RAF staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).
Western blot analysis of c-RAF expression in A431 (A); HeLa (B); RAW264.7 (C); C6 (D) whole cell lysates.
Western blot analysis of extracts from HT-29 cells, using Raf1 (Ab-341) antibody.The lane on the right is treated with the synthesized peptide.
Western blot analysis of extracts from HeLa cells, treated with UV (5mins), using Raf1 (Ab-621) antibody.The lane on the right is treated with the synthesized peptide.
Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue using Raf1 (Ab-621) antibody.The picture on the right is treated with the synthesized peptide.
Immunofluorescence analysis of HeLa cells, using Raf1 (Ab-621) antibody.The picture on the right is treated with the synthesized peptide.
Western blot analysis of extracts from CoLo cells, using C-RAF (Ab-642) Antibody.The lane on the right is treated with the synthesized peptide.
Anti-RAF1 antibody IHC of human kidney. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 10 ug/ml.
Western blot analysis of C-raf in 3T3 cell lysate with C-raf antibody at (A) 0.5 and (B) 1 ug/mL.
Western blot analysis of C-RAF expression in PMA treated NIH-3T3 whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis of C-RAF expression in UV treated HeLa whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis on Jurkat cell lysate using C-RAF Antibody
Western blot analysis of c-RAF expression in Hela (A) whole cell lysates.
Immunohistochemical analysis of c-RAF staining in human colon cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
The image on the left is immunohistochemistry of paraffin-embedded Human colon cancer tissue using (RAF1 Antibody) at dilution 1/40, on the right is treated with fusion protein. (Original magnification: ×200)
Western blot analysis of C-RAF phosphorylation expression in UV treated HeLa whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis of C-RAF phosphorylation expression in PMA treated NIH-3T3 whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis of C-RAF phosphorylation expression in PMA treated 293 whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot analysis of C-RAF phosphorylation expression in K562 whole cell lysates,The lane on the left is treated with the antigen-specific peptide.
Western blot of UV treated human Jurkat cell lysate showing specific immunolabeling of the ~74k Raf-1 protein (Control). The phosphospecificity of this labeling is shown in the second lane (lambda-phosphatase: λ-Ptase). The blot is identical to the control except that it was incubated in λ-Ptase (1200 units for 30 min) before being exposed to the phospho Ser301 Raf-1 antibody. The immunolabeling of Raf-1 is completely eliminated by treatment with λ-Ptase.
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| AP05628PU-N | RAF1 pSer642 antibody |
||||||
 |
Rabbit | IgG | Purified | Bov, Can, Chk, Hu, Mky, Ms, Rt | WB |
0.1 ml /
€590.00
|
|
| OriGene Technologies GmbH | |||||||
